Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Motif Bio: Latest data burnishes the credentials of new antibiotic

iclaprim is being developed to treat serious skin infections
researcher using microscope
Much of the latest data comes from two phase III clinical trials carried out by Motif

Data will be presented at a conference that suggests Motif Bio Plc’s (LON:MTFB) next-generation antibiotic has a number of advantages over the current crop of drugs designed to combat infection.

A review of the two phase III studies carried out on iclaprim showed there were fewer adverse events among diabetic patients taking the drug than those on the standard of care, a treatment called Vancomycin.

Drilling down, the statistical read-out showed no patients in the iclaprim group developed kidney injury, compared with three on Vancomycin.

Additionally, only 3.6% of the iclaprim group had to be taken off the drug compared with 10% receiving the standard of care.

Separately, surveillance data from work performed in the lab has confirmed iclaprim has the potential to work against a wide variety of Gram-positive bacteria, including drug-resistant strains.

Need for new antibiotics

"Given the worldwide crisis in antibiotic resistance, there remains a major need for new antibiotic treatments,” said David Huang, Motif’s chief medical officer.

“We have shown comprehensive data indicating that iclaprim has potent activity against a wide variety of Gram-positive bacteria, including MRSA that cause severe skin infections.”

The latest statistical update will be presented later Wednesday at an industry conference being held in Lisbon.

After successfully negotiating two phase III clinical trials a new drug submission has been made to the US Food & Drug Administration, which will come back with a decision on iclaprim in February next year.

Initially, the antibiotic will be used to treat acute bacterial skin and skin structure infections.

View full MTFB profile View Profile

Motif Bio Plc Timeline

Related Articles

man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use